NEW YORK (GenomeWeb) – Research enabled by GenomeDx's Decipher GRID data-sharing network continues to yield data on both new and existing gene expression signatures with prognostic or predictive value for prostate cancer patients.
The most recent insight, discussed earlier this month in a study in JAMA Oncology, speaks to the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic four years ago.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
